Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study highlights that scalp hair loss is an underreported side effect of somatostatin analogs therapy, potentially linked to decreased GH/IGF-1 levels or a direct drug effect.

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.

In this study, a new Finasteride conjugate showed stronger inhibition of 5α-reductase and similar reduction of prostate hyperplasia in rats compared to Finasteride, with potentially improved toxicity.

This study found that both finasteride and metformin effectively reduced androgen levels and insulin resistance parameters in women with PCOS, without clear evidence of one treatment being superior.

This review discusses existing and emerging treatments for hirsutism, highlighting new home-use laser devices, and reports no new clinical results; the authors note that permanent hair removal remains elusive.

This review found that finasteride may reduce bleeding during or after TURP procedures compared to placebo, although the overall results were varied, and no long-term complications were reported.

This study found significantly elevated central corneal thickness and intraocular pressure in patients with polycystic ovary syndrome, suggesting it should be considered in evaluating anterior segment diseases and glaucoma in women.

In this study, iontophoresis of medroxyprogesterone acetate significantly reduced hair growth rate in women with idiopathic facial hirsutism, without affecting serum androgen levels, and was well-tolerated as a treatment option.

This study reported a significant association between severe teenage acne and an increased risk of melanoma, potentially linked to androgen levels, though causation cannot be confirmed.

Hormonal therapy is effective for treating acne in adult women, especially with signs of high androgen levels.

This review discusses strategies for managing dermatological symptoms of hyperandrogenism in PCOS by reducing androgen levels and actions, and reports no new clinical results.

In this study, 85.9% of 120 hirsute Saudi women exhibited elevated androgen levels, suggesting the need for a comprehensive hormonal evaluation to identify underlying causes of hirsutism.

This study reports that two oral hormonal agents, dimethandrolone undecanoate and 11β-methylnortestosterone dodecylcarbonate, may effectively suppress hormones to contraceptive levels in men with mild side effects, though longer-term trials are required to confirm their safety and efficacy.

This review discusses the link between PCOS and acne, highlighting the roles of hyperandrogenism and insulin resistance, but it reports no new clinical findings.

This systematic review reported that among men taking finasteride for benign prostatic hyperplasia, total PSA levels decreased by 30% to 50%, and free PSA by up to 45%, with reductions in prostate volume and PSA density observed as well.

In this study, researchers examined androgen receptor activity in the adult mouse brain and found specific expression in key brain areas, which could inform understanding of cognitive side effects in humans undergoing androgen deprivation therapy for prostate cancer.

This study reports that dutasteride, used alone or with tamsulosin, effectively reduces acute urine retention and surgery risk in men with benign prostatic hyperplasia, and may lower prostate cancer incidence, suggesting potential chemopreventive benefits.

This review discusses the potential use of prostate specific antigen as a diagnostic marker for hyperandrogenism in polycystic ovary syndrome but reports no new clinical results and calls for further research.

Inclusive and affirming healthcare is essential for improving transgender individuals' quality of life and health.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

The authors concluded that preoperative treatment with finasteride for a month effectively reduced perioperative bleeding and shortened hospital stays in patients undergoing transurethral resection of the prostate.

This article updates on the medical management of benign prostatic hyperplasia in companion animals and reports no new clinical findings; the authors discuss existing treatments.

In this study, hormonal abnormalities were detected in all investigated hirsute Saudi women, with elevated major androgens in 85.9% and polycystic ovaries in 59% of cases.

Cyclosporin A and FK506 can start new hair growth in mice, but ascomycin and rapamycin cannot.

This study suggests that the use of finasteride and dutasteride may be linked to a decreased risk of melanoma in white men aged ≥60 years who have benign or malignant prostate tumors.

This review discusses advances in 5α-reductase inhibitors for treating male androgenetic alopecia and reports no new clinical results.

This review discusses the use of antiandrogens like flutamide and its derivatives in prostate cancer treatment and highlights the need for next-generation antiandrogens for improved efficacy; it reports no new clinical results.

This study found that Diane 35 combined with finasteride led to a greater reduction in hirsutism scores over 12 months compared to Diane 35 alone.

This study found that both high-dose and low-dose finasteride significantly reduced hirsutism scores in women after 12 months, with the lower dose being safe and cost-effective.

In this study, both cyproterone acetate-estrogen combination (Diane®) and finasteride were effective in reducing hirsutism, but Diane® showed greater long-term efficacy and cost-effectiveness.